STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment
Tenax Therapeutics will soon report results from a Phase 3 study that is one of the biggest binary biotech stock events remaining in the sector this year.
source
Reporting by STAT. The original article may no longer be reachable at its published URL.
read at STAT ↗
comments(0)
5-min edit window · permanent after that